Phase II trial of S-1+oxaliplatin+Cetuximab as first-line treatment in patients with kras-wild type unresectable advanced colorectal cancer - KODK 9 -
Ontology highlight
ABSTRACT: Interventions: (SOX+Cmab) L-OHP 85mg/m2 i.v.(day1) Cmab 500mg/m2 i.v.(day1) S-1 80mg/m2(day1-7) to be repeated every 2 weeks
Primary outcome(s): Response rate
Study Design: Single arm Non-randomized
DISEASE(S): Colorectal Cancer
PROVIDER: 2624365 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA